Cipla signs a non-exclusive patent license agreement with Takeda to commercialize Vonoprazan drug in India

Mumbai, June 20, 2024: Cipla Limited, hereafter referred to as “Cipla” (BSE: 500087; NSE: CIPLA EQ,) today announced that it has signed a non-exclusive Patent License agreement with Takeda Pharmaceutical Company Limited for ‘Vonoprazan’ for India Market for treating acid-related illnesses among patients. This deal is meant to commercialise the drug in India under Cipla’s own trademark brands.

Vonoprozan (oral tablets) is a novel potassium-competitive acid blocker (P-CAB), used for the treatment of related disorders - Gastroesophageal Reflux Disease (GERD). Vonoprozan will help in treating disorders such as erosive oesophagitis, gastric ulcer, duodenal ulcer, peptic ulcer, gastro- oesophageal reflux, reflux oesophagitis and Helicobacter pylori eradication.

Mr. Achin Gupta, CEO – One India Business, Cipla Limited, said: “Bringing new and advanced therapies to the Indian market has always been a key area of focus for us. We believe this partnership will not only address a significant medical need, but also strive to provide a better quality of life for patients.”